Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Matinas BioPharma (MTNB) stocks in Canada

Learn how to easily invest in Matinas BioPharma stocks.

Matinas BioPharma is a biotechnology business based in the US. Matinas BioPharma stocks (MTNB.US) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $0.7424 – an increase of 3.45% over the previous week. Matinas BioPharma employs 20 staff and has a trailing 12-month revenue of around $95,833.

How to buy shares in Matinas BioPharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MTNB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Matinas BioPharma stock price (NYSE MKT:MTNB)

Use our graph to track the performance of MTNB stocks over time.

Matinas BioPharma shares at a glance

Information last updated 2022-01-17.
Latest market close$0.90
52-week range$0.67 - $1.73
50-day moving average $1.02
200-day moving average $0.93
Wall St. target price$2.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.11

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Matinas BioPharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Matinas BioPharma price performance over time

Historical closes compared with the close of $0.9 from 2022-01-19

1 week (2022-01-13) 3.45%
1 month (2021-12-20) -14.29%
3 months (2021-10-20) -21.05%
6 months (2021-07-20) 27.30%
1 year (2021-01-20) -43.75%
2 years (2020-01-17) -39.60%
3 years (2019-01-18) 1.12
5 years (2017-01-20) 2

Matinas BioPharma financials

Revenue TTM $95,833
Gross profit TTM $-14,200,585
Return on assets TTM -21.61%
Return on equity TTM -36.26%
Profit margin 0%
Book value $0.27
Market capitalisation $189.2 million

TTM: trailing 12 months

Matinas BioPharma share dividends

We're not expecting Matinas BioPharma to pay a dividend over the next 12 months.

Matinas BioPharma share price volatility

Over the last 12 months, Matinas BioPharma's shares have ranged in value from as little as $0.668 up to $1.73. A popular way to gauge a stock's volatility is its "beta".

MTNB.US volatility(beta: 2.14)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Matinas BioPharma's is 2.1394. This would suggest that Matinas BioPharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Matinas BioPharma overview

Matinas BioPharma Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Stocks similar to Matinas BioPharma

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site